Fortress Biotech (FBIO)
(Delayed Data from NSDQ)
$1.79 USD
-0.11 (-5.79%)
Updated Jun 18, 2024 03:59 PM ET
After-Market: $1.80 +0.01 (0.56%) 5:32 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Brokerage Reports
Fortress Biotech, Inc. [FBIO]
Reports for Purchase
Showing records 81 - 100 ( 316 total )
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
BUY: FBIO Cash, Catalysts and Solid Fundamentals; Raising the Price Target from $22 to $24
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Journey Grows its Products; Lots of Partner Catalysts Coming
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Ximino/Targadox Tracker - Week ending 2/26/2021
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Ximino/Targadox Tracker - Week ending 2/19/2021
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Partner Model Continues to Work; Cyprium Licenses CUTX-101; Strong Cash Infusions Expected
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Ximino/Targadox Tracker - Week ending 2/12/2021
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
BUY: FBIO Tramadol Advances - Raising PT to $21
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Ximino/Targadox Tracker - Week ending 1/29/2021
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S